Back

Comparative efficacy of renin-angiotensin aldosteron system modulators and angiotensin receptor neprilyzin inhibitor in chronic heart failure with reduced, mid-ranged and preserved ejection fraction

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Liana Tumasyan

Institute of Cardiology of Yerevan, Yerevan (Armenia)

9 More presentations in this session

Presentation thumbnail
Effect of beta-blockers on mortality in heart failure with mid-range and preserved ejection fraction: a meta-analysis
Associate Professor H. Fukuta (Nagoya, JP)
Abstract
Presentation thumbnail
The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction
Doctor C. Wei-Ting (Tainan, TW)
Abstract Slides
Presentation thumbnail
Change in left ventricular ejection fraction and outcome in heart failure patients with mid-range ejection fraction: from the HIJ-HF prospective study
Doctor K. Tsukamoto (Tokyo, JP)
Abstract
Presentation thumbnail
Natriuretic peptides added to clinical parameters predict two-year prognosis of patients with chronic heart with mid-range and reduced ejection fraction.
Professor J. Spinar (Brno, CZ)
Abstract Slides
Presentation thumbnail
Rehospitalization burden in heart failure with mid-range ejection fraction and morbidity burden. Is it a distinct phenotype?
Doctor E. Santas Olmeda (Valencia, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources